Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
NCT03406000
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
170
Enrollment
INDUSTRY
Sponsor class
Conditions
Type I Diabetes Mellitus
Interventions
DRUG:
INSULIN GLARGINE (U300)
Sponsor
Sanofi